We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks Jon.....Interesting find...it underlines the
quality of Pharmas with links to HEMO and the
groundbreaking potential here.....They could
indeed be the globalco....When the news
lands we will see a great return for the patient
investors here...and of course we await updates
on other projects in our pipeleine.....
I think we have got rid of a lot of rainbow chasers
just interested in the next Covid play who did not
do any research and had little to no idea of what
HEMO are reserching....That is a good thing as I
beliveve most PI's still invested here know significant
news will land in the next few weeks/months and
are holding for RNS. So, that should see the SP
stabilise and rise. I suspect HEMO is on many watchlists
and once it is established the bottom has been hit they
wil take a position as it should start to rise from here IMHO.
Would be great to get a TR1 tomorrow..If the placing shares
are held then that would mean there is not a lot of free float
so we could enter a more interesting phase...funded...news due..............
GLA!
My main point was the $500 Million Breakthrough Growth Initiative announced by Pfizer on the 2nd of June for companies with small- to medium-sized market capitalizations. A very small connection to Hemogenyx having an advisor with connections, but just thought it was relevant.
Could he really remain CEO of Biopharma Solutions yet be a Business Development Advisor for Hemo. I would have thought that would be a conflict of interest?
Given his history and seniority. Perhaps it would warrant an RNS?
He's showing as an advisor on the website. Do they need to announce a new advisor? Maybe not. This all sounds like it's heading in the right direction for a change. Should be some upward movement Monday am. However we still need a real progress announcement to really get things moving. I'm up to 75,000 shares now. I will buy on every drop.GLA
Sorry: I meant Manhattan Biosolutions. Not pharma.
Anyone know if Dr Boris Shor is a new addition to the Hemo team? I can't find any google reference for his appointment in a non exec/advisory role or otherwise. Appears that he was CEO of Manhatttan Biopharma in May 2020
Thanks for that Jon441cc, very interesting. I've posted a link on twitter
Hmmm. Interesting :-)
Dr Boris Shor Ph.D. is the business development advisor for Hemogenyx pharmaceuticals
Jon. How did Dr Boris come to be on your radar?
The Pfizer Breakthrough Growth Initiative will focus on making non-controlling equity investments in clinical-stage public companies, with a primary focus on companies with small- to medium-sized market capitalizations across a range of therapeutic categories that are consistent with Pfizer’s core areas of focus: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines and Hospital. Partner companies may also have the opportunity to access Pfizer’s significant expertise and resources in research, clinical development and manufacturing.
Dr Boris Shor Ph.D
BUSINESS DEVELOPMENT ADVISOR
Currently a group leader at the Oncology Research Unit of Pfizer in New York. His team focuses on the discovery and early development of new antibody-drug conjugates (ADCs) and supports translational research efforts for the late stage assets. Dr. Shor also serves as a nonclinical pharmacology representative on the late stage clinical program, supporting BLA filings with worldwide regulatory authorities. In addition, Dr. Shor is routinely involved in accessing emerging sciences, R&D technology platforms and therapeutic products in US, Israel and Europe to ensure strategic integration of external opportunities in disease areas of interests to Pfizer.
Any thouoghts ; )
I was lucky enough to get in before the 15p spike as info was posted on the TLW BB and I have been topping up in the low 7s and 6s ever since with profits. I did not think it would go back into 6s but news or the lack of has not treated this share well.
The 7p placing, no update on orgenesis collab and 3 month Extension on CDX have hampered the share massively, but that is no reason to cut and run.
By no means am I an expert on the stock market or this company, but I have researched as much as I can and invested in a company with a fantastic future.
Hu-PHEC Stem cell tech and CDX antibodies........... A LIFE SAVING COMPANY.
IP on all ongoing Tech.
Both...Arthur!
Anton nobody is listening to your non stop tripe. You're either a shorter or a pillock, cant decide which at this stage.
Imo the only way is up now. There nay be some wobbles on the way but:
Placement done and now out of the way.
Global Co. Delay until end of August.
So that's the bad stuff.
The good stuff:
Covid collaborations
Orgenesis deal and potential royalties
Other co.s using Hemo mice
Own Car-T develpments
Global Co in a couple of months
An RNS could drop at any time. So imo buy the dips and hold.
Imo 20-25p by September. 25-50p by end of year.